What this pack is
Zyprexa is the brand name in this record; olanzapine is the generic name. Read both together with the dosage form (multiple forms (oral tablets and injectable product)).
PACK CHECK · MARKET FIRST
ZyprexaGeneric nameolanzapine
How this medicine works
The U.S. ZYPREXA label says olanzapine's mechanism in the listed indications is unclear and describes a possible combination of dopamine and serotonin type 2 (5HT2) antagonism. This explains a labelled pharmacologic pathway; it does not predict anyone's symptoms, response, suitability, tablet count, injection plan or co-use outcome.
Read source: United States ↗Current regulatory record · reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- Zyprexa
- Generic name
- olanzapine
- Dosage-form class
- Regular oral tablets: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg (as listed in the U.S. public label; this dossier establishes six exact 30-tablet bottle identities; not merged with ZYDIS orally disintegrating tablets or injections)
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
6 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. DailyMed public label (SPL v68, published 16 Feb 2026; label revised Jan 2026); cited public-label panel only, not availability
Olanzapine 2.5 mg per tablet; 30-tablet bottle
- Product code
- NDC 61269-630-30
- Form and route
- ZYPREXA olanzapine regular oral tablet (not ZYDIS orally disintegrating tablet or injection) · oral (label product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-23; actual marketing, stock and availability are not established.
- olanzapine
- 2.5 mglabelled amount per tablet; not an individual's tablet count, splitting, co-use, stopping or switching instruction
- Package
- 30 tablets per bottle
- Labelled appearance
- white · round tablet; no score · imprint LILLY / 4112Unscored in this labelled presentation
United States label · Current U.S. DailyMed public label (SPL v68, published 16 Feb 2026; label revised Jan 2026); cited public-label panel only, not availability
Olanzapine 5 mg per tablet; 30-tablet bottle
- Product code
- NDC 61269-631-30
- Form and route
- ZYPREXA olanzapine regular oral tablet (not ZYDIS orally disintegrating tablet or injection) · oral (label product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-23; actual marketing, stock and availability are not established.
- olanzapine
- 5 mglabelled amount per tablet; not an individual's tablet count, splitting, co-use, stopping or switching instruction
- Package
- 30 tablets per bottle
- Labelled appearance
- white · round tablet; no score · imprint LILLY / 4115Unscored in this labelled presentation
United States label · Current U.S. DailyMed public label (SPL v68, published 16 Feb 2026; label revised Jan 2026); cited public-label panel only, not availability
Olanzapine 7.5 mg per tablet; 30-tablet bottle
- Product code
- NDC 61269-632-30
- Form and route
- ZYPREXA olanzapine regular oral tablet (not ZYDIS orally disintegrating tablet or injection) · oral (label product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-23; actual marketing, stock and availability are not established.
- olanzapine
- 7.5 mglabelled amount per tablet; not an individual's tablet count, splitting, co-use, stopping or switching instruction
- Package
- 30 tablets per bottle
- Labelled appearance
- white · round tablet; no score · imprint LILLY / 4116Unscored in this labelled presentation
United States label · Current U.S. DailyMed public label (SPL v68, published 16 Feb 2026; label revised Jan 2026); cited public-label panel only, not availability
Olanzapine 10 mg per tablet; 30-tablet bottle
- Product code
- NDC 61269-633-30
- Form and route
- ZYPREXA olanzapine regular oral tablet (not ZYDIS orally disintegrating tablet or injection) · oral (label product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-23; actual marketing, stock and availability are not established.
- olanzapine
- 10 mglabelled amount per tablet; not an individual's tablet count, splitting, co-use, stopping or switching instruction
- Package
- 30 tablets per bottle
- Labelled appearance
- white · round tablet; no score · imprint LILLY / 4117Unscored in this labelled presentation
United States label · Current U.S. DailyMed public label (SPL v68, published 16 Feb 2026; label revised Jan 2026); cited public-label panel only, not availability
Olanzapine 15 mg per tablet; 30-tablet bottle
- Product code
- NDC 61269-634-30
- Form and route
- ZYPREXA olanzapine regular oral tablet (not ZYDIS orally disintegrating tablet or injection) · oral (label product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-23; actual marketing, stock and availability are not established.
- olanzapine
- 15 mglabelled amount per tablet; not an individual's tablet count, splitting, co-use, stopping or switching instruction
- Package
- 30 tablets per bottle
- Labelled appearance
- blue · elliptical tablet; no score · imprint LILLY / 4415Unscored in this labelled presentation
United States label · Current U.S. DailyMed public label (SPL v68, published 16 Feb 2026; label revised Jan 2026); cited public-label panel only, not availability
Olanzapine 20 mg per tablet; 30-tablet bottle
- Product code
- NDC 61269-635-30
- Form and route
- ZYPREXA olanzapine regular oral tablet (not ZYDIS orally disintegrating tablet or injection) · oral (label product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-23; actual marketing, stock and availability are not established.
- olanzapine
- 20 mglabelled amount per tablet; not an individual's tablet count, splitting, co-use, stopping or switching instruction
- Package
- 30 tablets per bottle
- Labelled appearance
- pink · elliptical tablet; no score · imprint LILLY / 4420Unscored in this labelled presentation
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
ZYPREXA label reading: keep regular tablets, orally disintegrating tablets, injections and mg markings separate
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module uses the U.S. public label to check ZYPREXA, olanzapine, regular oral tablets, stated strength per tablet, the exact pack and target market; it provides no individual tablet count, schedule, missed-use remedy, co-use, switching, splitting or stopping advice.
- 2.5, 5, 7.5, 10, 15 and 20 mg are stated amounts per regular tablet in the current label, not an answer to ‘how many tablets today.’ The image on this page is only for 10 mg, NDC 61269-633-30, a 30-tablet bottle; a matching name, colour or mg marking does not establish that another pack is the same product.
- ZYPREXA ZYDIS is an orally disintegrating tablet, ZYPREXA IntraMuscular is an intramuscular injection, and ZYPREXA RELPREVV is a separate long-acting injection. Do not self-change form, combine, alternate, replace tablets with an injection or infer splitting from package numbers merely because they share olanzapine or the ZYPREXA brand family; have the actual prescription and current label reviewed by the prescribing team or pharmacist.
- The U.S. label carries an important limitation for elderly people with dementia-related psychosis: ZYPREXA is not approved for that population. This is a label-reading prompt, not a web diagnosis or treatment conclusion for any person; with older age, cognitive change, falls, fainting, drowsiness or multiple medicines, ask the local care team to review every medicine and actual pack promptly.
- The label identifies co-medication review cues including medicines that can affect blood pressure, levodopa/dopamine agonists, and lorazepam in a specific intramuscular context. They do not let a website decide whether a person can use them together, how to separate them, or how to change or replace anything; take the complete medicine list and actual packs to a pharmacist or clinician for item-by-item review.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. ZYPREXA olanzapine regular-tablet, ZYDIS orally-disintegrating-tablet and intramuscular-injection public label (H2-Pharma LLC; SPL v68, published 16 Feb 2026) ↗Current regulatory record · reviewed 2026-08-20
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Zyprexa (olanzapine). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Zyprexa is the brand in this record and olanzapine is the active-ingredient name. Check both with the dosage form (Regular oral tablets: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg (as listed in the U.S. public label; this dossier establishes six exact 30-tablet bottle identities; not merged with ZYDIS orally disintegrating tablets or injections)) and the market on the actual pack.
Read the labelled strength in context
mg/mL, mg per vial or a total volume describes the labelled concentration or pack identity of an injectable product. It is not an individual infusion amount, preparation instruction or schedule.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a severe reaction, fainting, difficulty breathing or sudden worsening symptoms around an injection or infusion, use the local treatment team or emergency service now. Do not wait for a website reply or alter preparation, infusion or another medicine yourself.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
HOW IT WORKS · NOT A TREATMENT PLAN
How olanzapine works: the label describes several receptor actions, not a guide for personal adjustment
- “Acts on dopamine and serotonin receptors” is one clue for understanding a medicine class; it is not a website tool for deciding the cause of hallucinations, mood, sleep, behavioural or cognitive changes, and cannot replace professional judgement using the exact diagnosis, course and complete medicine list.
- Being antipsychotic medicines, involving related receptors or both potentially causing drowsiness does not permit self-combination, replacement, alternation or milligram conversion between ZYPREXA, SEROQUEL or another product. Brand, exact form, release characteristics, prior reactions, health context and the complete medicine list all need item-by-item professional review.
- A mechanism explanation cannot manage sudden severe drowsiness, fainting, a fall, fever with muscle rigidity, chest discomfort or marked behavioural change. With an acute or serious concern, prioritise local medical and emergency support rather than experimenting with forms or adjusting from package numbers.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
SOURCE-TRACEABLE ARCHIVE
Zyprexaolanzapine
This page includes an exact current U.S. public-label package panel for Zyprexa, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval year listed in the current label
The current ZYPREXA label lists Initial U.S. Approval: 1996. This year locates this U.S. archive only; it does not establish approval, supply or sale status in another market.
DailyMed (NLM): current U.S. ZYPREXA olanzapine regular-tablet, ZYDIS orally-disintegrating-tablet and intramuscular-injection public label (H2-Pharma LLC; SPL v68, published 16 Feb 2026) ↗Current public SPL v68 published on DailyMed
DailyMed lists 16 Feb 2026 as the publication date for SPL v68, a combined ZYPREXA/ZYDIS/intramuscular-injection label. This page selects only the exact regular-tablet 10 mg package panel and does not extend it to orally disintegrating tablets, injections, another pack, stock or individual use.
DailyMed (NLM): current U.S. ZYPREXA olanzapine regular-tablet, ZYDIS orally-disintegrating-tablet and intramuscular-injection public label (H2-Pharma LLC; SPL v68, published 16 Feb 2026) ↗
MARKET SCOPE
Market-record boundary
United States
Regular-tablet public label and exact 10 mg package panel linkedThe displayed panel only corresponds to regular oral 10 mg tablets, NDC 61269-633-30, in a 30-tablet bottle; it does not establish actual availability, stock, individual tablet count, splitting, co-use or another-strength status.
U.S. ZYDIS, intramuscular injection, RELPREVV and Mainland China, EU, Japan and other markets
Explicitly separate or market record not establishedZYDIS orally disintegrating tablets, intramuscular injection and RELPREVV long-acting injection are different product presentations. This regular-tablet label does not establish a trade name, approval, strength, pack, supply, sale eligibility, originator/generic relationship or interchangeability for those products or another market.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
ZYPREXA, ZYDIS and injections all contain olanzapine. Can they be self-converted by mg?
No. This page establishes the U.S. public-label reading path for regular oral tablets only; ZYDIS, intramuscular injection and RELPREVV are different product presentations. A shared ingredient, brand family or similar mg marking cannot establish self-substitution, co-use, alternation or proportional splitting. A pharmacist or prescribing team must review the actual prescription, complete medicine list and current target-market label.
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.